Reply to: The Role of Risk-Reducing Bilateral Mastectomy in BRCA1 and BRCA2 Pathogenic Variant Carriers

Ashu Gandhi1, Sacha J Howell1, D Gareth Evans1

  • 1Ashu Gandhi, MD, Division of Cancer Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester, United Kingdom, Manchester University Hospitals, Manchester, United Kingdom, Manchester Academic Health Sciences Centre & Manchester Breast Centre, University of Manchester, Manchester, United Kingdom; Sacha J. Howell, PhD, Division of Cancer Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester, United Kingdom, Manchester University Hospitals, Manchester, United Kingdom, Manchester Academic Health Sciences Centre & Manchester Breast Centre, University of Manchester, Manchester, United Kingdom, Christie Hospital NHS Foundation Trust, Manchester, United Kingdom; and D. Gareth Evans, MD, Manchester University Hospitals, Manchester, United Kingdom, Manchester Academic Health Sciences Centre & Manchester Breast Centre, University of Manchester, Manchester, United Kingdom, Manchester Centre for Genomic Medicine, Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, Division of Evolution, Infection and Genomic Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.

Abstract

No abstract available in PubMed .